BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertension

By afschroeder • August 30, 2025

Sahay S, Palevsky H, El-Kersh K, Restrepo-Jaramillo R, Bajwa AA, Desai S, Joly JM, Spikes LA, Eggert MS, Johri S, Shapiro SM, Fisher MR, Shah TG, Ramani GV, Mehta JP, Thrasher CM, Deng C, Smith P, Broderick M, Burger CD. BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertension. Respir Med. 2025 Aug 27;248:108318. doi: 10.1016/j.rmed.2025.108318. Epub ahead of print. PMID: 40882760.

Tags: Cardiology/Epi, Dry powder inhaler, exercise capacity, Prostacyclin dosing, Publications, pulmonary arterial hypertension, Treprostinil, Veterans Administration

Comparative effectiveness of sodium-glucose cotransporter 2 inhibitors along with colchicine versus colchicine alone among coronary artery disease and type 2 diabetes patients

Jaiswal V, Hanif M, Kumar D, Mashkoor Y, Kumar T, Ahmed R, Mattumpuram J, Qamar A, Fonarow GC, Lavie CJ. Comparative effectiveness of sodium-glucose cotransporter[...]

Transgenic mice overexpressing Pitx2 in the atria develop tachycardia-bradycardia syndrome

Baba S, Shinjo S, Seya D, Bochimoto H, Akaike T, Nakano A, Minamisawa S. Transgenic mice overexpressing Pitx2 in the atria develop tachycardia-bradycardia syndrome. PLoS[...]

Predicting risk of cardiovascular events (PREVENT) score accuracy among people with HIV in the multicenter CNICS cohort

Durstenfeld MS, Nance RM, Jones R, Abelman R, Hoffmann AP, Burkholder G, Hsue PY, Longenecker CT, Hunt PW, Saag MS, Delaney JAC, Feinstein MJ, Crane[...]